GLPG0187: Safety, Tolerability and Pharmacokinetics in Patients With Solid Tumors

• Status: Completed
• Trial end date: 2013-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to determine the safety and tolerability of GLPG0187 administered through continuous intravenous infusion and to explore its preliminary clinical efficacy in patients with solid tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Galapagos NV

Criteria

Inclusion Criteria:

• Pathologically confirmed diagnosis of advanced, recurrent, or metastatic cancer who are refractory to standard therapy or for whom no standard therapy exist.

• Age of 18 years or older.

• Measurable (according to RECIST 1.1) and evaluable disease as determined by the Investigator.

• ECOG Performance Status ≤ 2.

• Estimated life expectancy of at least 12 weeks.

• Toxicities incurred as a result of previous anticancer therapy (radiation therapy, chemotherapy, or surgery) must be resolved to ≤ Grade 2.

• Written informed consent according to local guidelines.

Exclusion Criteria:

• Prior Treatment:

• Less than 4 weeks since the last treatment with other cancer therapies, (i.e. endocrine therapy, immunotherapy, chemotherapy, etc.), and < 6 weeks for nitrosoureas and Mitomycin C.

• Prior therapy with integrin receptor antagonists

• Current Treatment:

• Chronic daily treatment with corticosteroids (dose of 10 mg/day or more methylprednisolone or equivalent), with the exception of inhaled steroids.

• Current or recent (within 30 days of first study treatment) treatment with another investigational drug or participation in another investigational study.

• Hematology, coagulation and biochemistry:

• Inadequate bone marrow function: Absolute Neutrophil Count (ANC): < 1.5 x 10E9/L, or platelet count <100 x 10E9/L or hemoglobin < 6 mmol/L.

• Inadequate liver function, defined as:

• Serum (total) bilirubin > 2 x the Upper Limit of Normal (ULN) for the institution;

• Aspartate Amino Transferase (ASAT) or Alanine Amino Transferase (ALAT) > 2.5 x ULN (> 5 x ULN in subjects with liver metastases);

• Alkaline phosphatase levels > 2.5 x ULN (> 5 x ULN in subjects with liver metastases, or > 10 x ULN in subjects with bone metastases).

• Inadequate renal function, defined as:

• Serum creatinine > 1.5 x ULN

• Urine dipstick for proteinuria > 2+.

• Other:

• Clinically symptomatic or progressive brain metastases

• Clinical Leptomeningeal metastases

• Pregnancy or lactation. Serum pregnancy test to be assessed within 7 days prior to study treatment start, or within 14 days with a confirmatory urine pregnancy test within 7 days prior to study treatment start.

• For women of childbearing potential (defined as <2 years after last menstruation and not surgically sterile): absence of effective, non-hormonal means of contraception (intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal gel).

• Major surgical procedure (including open biopsy, excluding central line IV and portacath) within 28 days prior to the first study treatment, or anticipation of the need for major surgery during the course of the study treatment.

• Congestive heart failure NYHA Class III and IV. Cardiac arrhythmias (except for atrioventricular block type I, Mobitz type, and II, Wenckebach type) signs and symptoms of relevant cardiovascular disease.

• Known hypersensitivity to any of the study drugs or excipients.

• Evidence of any other medical conditions (such as psychiatric illness, infectious diseases, physical examination or laboratory findings) that may interfere with the planned treatment, affect subject compliance or place the subject at high risk from treatment-related complications.